Disease exacerbation by fibroblast inclusion in Duchenne Muscular Dystrophy MYOrganoids reveals limitations of microdystrophin therapeutic efficacy
L. Palmieri, L. Pili, A. Jaber, A. Vu Hong, M. Marcello, R. El Khoury, G. Brochier, A. Bigot, D. Israeli, I. Richard, S. Albini
This paper develops a human DMD model using MYOrganoids to study fibroblast inclusion effects and evaluates microdystrophin therapy efficacy, finding limited success in reducing fibrosis and improving membrane stability.
bioRxiv · Jul 26, 2023 · PreprintBioengineering